Replimune stock falls as FDA denies skin cancer drug approval and investors sue over alleged misstatements tied to the IGNYTE trial.
Why Is Replimune Stock Trading Lower On Monday?
Where Today's News Shapes Tomorrow
March 7, 2026
Headlines
